Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Accured Expenses (2016 - 2025)

Editas Medicine (EDIT) has disclosed Change in Accured Expenses for 11 consecutive years, with -$543000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 153.5% to -$543000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $8.5 million, a 327.56% increase, with the full-year FY2024 number at $1.3 million, down 29.39% from a year prior.
  • Change in Accured Expenses was -$543000.0 for Q3 2025 at Editas Medicine, down from $578000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $11.0 million in Q4 2022 to a low of -$9.6 million in Q1 2021.
  • A 5-year average of $805473.7 and a median of $1.0 million in 2024 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 652.71% in 2021; the steepest drop was 1248.02% in 2021.
  • Editas Medicine's Change in Accured Expenses stood at $9.4 million in 2021, then increased by 16.43% to $11.0 million in 2022, then plummeted by 83.82% to $1.8 million in 2023, then skyrocketed by 282.11% to $6.8 million in 2024, then crashed by 107.99% to -$543000.0 in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Change in Accured Expenses are -$543000.0 (Q3 2025), $578000.0 (Q2 2025), and $1.7 million (Q1 2025).